
Mary E Strek

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6066618/publications.pdf Version: 2024-02-01



MADY F STDEK

#	Article	IF	CITATIONS
1	Detection and Early Referral of Patients With Interstitial Lung Abnormalities. Chest, 2022, 161, 470-482.	0.4	26
2	Hypersensitivity pneumonitis: Current concepts in pathogenesis, diagnosis, and treatment. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 442-453.	2.7	28
3	Lung function trajectory in progressive fibrosing interstitial lung disease. European Respiratory Journal, 2022, 59, 2101396.	3.1	40
4	Interstitial Lung Disease in Firefighters: An Emerging Occupational Hazard. Frontiers in Medicine, 2022, 9, 864658.	1.2	6
5	Occupational Exposures in Rheumatoid Arthritis-Related Airway Disease: A Missing Link?. Annals of the American Thoracic Society, 2022, , .	1.5	0
6	Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2022, 205, e18-e47.	2.5	780
7	Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the <scp>Canadian Registry</scp> for <scp>Pulmonary Fibrosis</scp> . Respirology, 2022, 27, 635-644.	1.3	12
8	COVIDOSE: A Phase II Clinical Trial of Lowâ€Dose Tocilizumab in the Treatment of Noncritical COVIDâ€19 Pneumonia. Clinical Pharmacology and Therapeutics, 2021, 109, 688-696.	2.3	42
9	Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitis. European Respiratory Journal, 2021, 57, 2002872.	3.1	32
10	Differentiation of Idiopathic Pulmonary Fibrosis from Connective Tissue Disease-Related Interstitial Lung Disease Using Quantitative Imaging. Journal of Clinical Medicine, 2021, 10, 2663.	1.0	11
11	Characteristics and Prevalence of Domestic and Occupational Inhalational Exposures Across Interstitial Lung Diseases. Chest, 2021, 160, 209-218.	0.4	18
12	Association of antinuclear antibody seropositivity with inhaled environmental exposures in patients with interstitial lung disease. ERJ Open Research, 2021, 7, 00254-2021.	1.1	0
13	Hospitalizations in patients with idiopathic pulmonary fibrosis. Respiratory Research, 2021, 22, 257.	1.4	8
14	Rituximab for interstitial pneumonia with autoimmune features at two medical centres. Rheumatology Advances in Practice, 2021, 5, ii1-ii9.	0.3	7
15	Recent Advances in Severe Asthma. Chest, 2020, 157, 516-528.	0.4	96
16	Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 564-574.	2.5	208
17	Myositis-specific antibodies identify a distinct interstitial pneumonia with autoimmune features phenotype. European Respiratory Journal, 2020, 56, 2001205.	3.1	24
18	Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations. Blood Advances, 2020, 4, 4873-4886.	2.5	23

MARY E STREK

#	Article	IF	CITATIONS
19	Automated CT Analysis of Major Forms of Interstitial Lung Disease. Journal of Clinical Medicine, 2020, 9, 3776.	1.0	14
20	Gender equity in interstitial lung disease. Lancet Respiratory Medicine, the, 2020, 8, 842-843.	5.2	6
21	Recognition and Management of Myositis-Associated Rapidly Progressive Interstitial Lung Disease. Chest, 2020, 158, 252-263.	0.4	40
22	Gender in idiopathic pulmonary fibrosis diagnosis: time to address unconscious bias. Thorax, 2020, 75, 365-366.	2.7	4
23	Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis. Chest, 2020, 158, 1526-1534.	0.4	31
24	CPAP Adherence, Mortality, and Progression-Free Survival in Interstitial Lung Disease and OSA. Chest, 2020, 158, 1701-1712.	0.4	19
25	Prevalence and Clinical Significance ofÂAntineutrophil Cytoplasmic Antibodies inÂNorth American Patients With Idiopathic Pulmonary Fibrosis. Chest, 2019, 156, 715-723.	0.4	45
26	Diagnostic test interpretation and referral delay in patients with interstitial lung disease. Respiratory Research, 2019, 20, 253.	1.4	35
27	Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat. Respiratory Research, 2019, 20, 205.	1.4	166
28	Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 199-208.	2.5	90
29	T cell Co-Stimulatory molecules ICOS and CD28 stratify idiopathic pulmonary fibrosis survival. Respiratory Medicine: X, 2019, 1, 100002.	1.4	7
30	Anti-RNA binding protein positivity in idiopathic interstitial pneumonia. Respiratory Medicine, 2019, 146, 23-27.	1.3	1
31	Telomere length and genetic variant associations with interstitial lung disease progression and survival. European Respiratory Journal, 2019, 53, 1801641.	3.1	119
32	African-American race and mortality in interstitial lung disease: a multicentre propensity-matched analysis. European Respiratory Journal, 2018, 51, 1800255.	3.1	37
33	CT-Pathologic Correlation of Major Types of Pulmonary Fibrosis: Insights for Revisions to Current Guidelines. American Journal of Roentgenology, 2018, 210, 1034-1041.	1.0	26
34	Phenotypic Clusters Predict Outcomes in a Longitudinal Interstitial Lung Disease Cohort. Chest, 2018, 153, 349-360.	0.4	40
35	Asthma Outcomes and Management DuringÂPregnancy. Chest, 2018, 153, 515-527.	0.4	91
36	N-acetylcysteine exposure is associated with improved survival in anti-nuclear antibody seropositive patients with usual interstitial pneumonia. BMC Pulmonary Medicine, 2018, 18, 30.	0.8	5

MARY E STREK

#	Article	IF	CITATIONS
37	Systemic sclerosisâ€associated interstitial lung disease: Role of the oesophagus in outcomes. Respirology, 2018, 23, 885-886.	1.3	3
38	Allergic and Noninvasive Infectious Pulmonary Aspergillosis Syndromes. Clinics in Chest Medicine, 2017, 38, 521-534.	0.8	33
39	CT Findings, Radiologic-Pathologic Correlation, and Imaging Predictors of Survival for Patients With Interstitial Pneumonia With Autoimmune Features. American Journal of Roentgenology, 2017, 208, 1229-1236.	1.0	47
40	De Novo Development of Bronchiectasis in Patients With Hematologic Malignancy. Chest, 2017, 152, 683-685.	0.4	12
41	Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis. ERJ Open Research, 2017, 3, 00016-2017.	1.1	84
42	Myositis-associated Interstitial Lung Disease: Predictors of Failure of Conventional Treatment and Response to Tacrolimus in a US Cohort. Journal of Rheumatology, 2017, 44, 1612-1618.	1.0	40
43	Interstitial pneumonia with autoimmune features: Clinical, radiologic, and histological characteristics and outcome in a series of 57 patients. Respiratory Medicine, 2017, 123, 56-62.	1.3	119
44	Comprehensive Care of the Lung Transplant Patient. Chest, 2017, 152, 150-164.	0.4	74
45	Autoimmune Hypothyroidism As a Predictor of Mortality in Chronic Hypersensitivity Pneumonitis. Frontiers in Medicine, 2017, 4, 170.	1.2	10
46	Skewed Lung CCR4 to CCR6 CD4+ T Cell Ratio in Idiopathic Pulmonary Fibrosis Is Associated with Pulmonary Function. Frontiers in Immunology, 2016, 7, 516.	2.2	29
47	A call for uniformity in implementing the IPAF (interstitial pneumonia with autoimmune features) criteria. European Respiratory Journal, 2016, 48, 1813-1814.	3.1	8
48	The Diagnosis and Treatment of Antisynthetase Syndrome. Clinical Pulmonary Medicine, 2016, 23, 218-226.	0.3	151
49	Predictors of survival in coexistent hypersensitivity pneumonitis with autoimmune features. Respiratory Medicine, 2016, 114, 53-60.	1.3	42
50	Characterisation of patients with interstitial pneumonia with autoimmune features. European Respiratory Journal, 2016, 47, 1767-1775.	3.1	219
51	Therapeutic Approach to Adult Fibrotic Lung Diseases. Chest, 2016, 150, 1371-1386.	0.4	39
52	Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease. Respiratory Medicine, 2016, 121, 117-122.	1.3	85
53	Response. Chest, 2016, 149, 600-601.	0.4	0
54	Treatment of Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2016, 13, 115-117.	1.5	19

MARY E STREK

#	Article	IF	CITATIONS
55	Thyroid Disease Is Prevalent and Predicts Survival in Patients With Idiopathic Pulmonary Fibrosis. Chest, 2015, 148, 692-700.	0.4	50
56	A functional genomic model for predicting prognosis in idiopathic pulmonary fibrosis. BMC Pulmonary Medicine, 2015, 15, 147.	0.8	42
57	An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. European Respiratory Journal, 2015, 46, 976-987.	3.1	803
58	<i>TOLLIP</i> , <i>MUC5B</i> , and the Response to <i>N</i> -Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1475-1482.	2.5	257
59	Diagnosis and Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease. Chest, 2013, 143, 814-824.	0.4	257
60	Barriers to Optimal Palliative Care of Lung Transplant Candidates. Chest, 2013, 143, 736-743.	0.4	60
61	Bronchiectasis in a Diverse US Population. Chest, 2012, 142, 159-167.	0.4	88
62	Improving Asthma Management. Chest, 2012, 142, 1085-1087.	0.4	3
63	Autoimmune-Featured Interstitial Lung Disease. Chest, 2011, 140, 1292-1299.	0.4	236
64	Difficult Asthma. Proceedings of the American Thoracic Society, 2006, 3, 116-123.	3.5	30
65	Consensus guidelines for asthma therapy. Annals of Allergy, Asthma and Immunology, 2001, 86, 40-44.	0.5	18